Use of Insulin Glargine to Treat Diabetic Ketoacidosis
Use of Insulin Glargine to Treat Diabetic Ketoacidosis
The purpose of this study is to determine the effects of the addition of insulin glargine
 during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children.

 The investigators hypothesize that the addition of insulin glargine during the early phase of
 management of DKA will accelerate acidosis correction, decrease the length of insulin
 infusion, and decrease the total intensive care unit time in children admitted to the ICU.
Inclusion Criteria:

 -  Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with:

 -  Established history of insulin dependent diabetes

 AND:

 -  Chief c/o hyperglycemia or vomiting

 -  Venous pH < 7.24

 -  Serum Bicarbonate < 18

 -  Blood glucose > 150

 -  Urinary Ketones

 Exclusion Criteria:

 -  Age < 6y.o.

 -  New onset diabetes

 -  Received IV insulin bolus prior to arrival to VCH Emergency Room (ER)

 -  Venous pH > 7.24

 -  Serum Bicarbonate > 18

 -  Pregnancy

 -  Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric
 Critical Care Unit